The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | Novel adoptive transfer mouse models in CLL
Elisa ten Hacken, PhD from the Dana-Farber Cancer Institute, Boston, MA provides an overview of her presentation given at the Young Investigator Meeting during the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY. The focus of Dr ten Hacken’s research is the development of in vivo mouse models to study novel CLL driver mutations. In her presentation, Dr ten Hacken describes one of these models which includes two concurrent CLL driver mutations, Sf3b1mut/Atmdel. Once these mouse models have been established, the aim is to use them as treatment platforms for novel agents.
